HSBC: Lowered its target price for Novo Nordisk from 320 Danish kroner to 280 Danish kroner; lowered its target price for Bristol-Myers Squibb from $65 to $60; and lowered its target price for AstraZeneca from 13,920 pence to 13,900 pence.
2026-10-19
HSBC: Lowered its target price for Novo Nordisk from 320 Danish kroner to 280 Danish kroner; lowered its target price for Bristol-Myers Squibb from $65 to $60; and lowered its target price for AstraZeneca from 13,920 pence to 13,900 pence.